Compare REGN & WBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | WBD |
|---|---|---|
| Founded | 1988 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5B | 69.9B |
| IPO Year | 1995 | 2008 |
| Metric | REGN | WBD |
|---|---|---|
| Price | $755.72 | $27.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 21 |
| Target Price | ★ $821.08 | $23.78 |
| AVG Volume (30 Days) | 499.1K | ★ 23.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | 8.19 | ★ 106.28 |
| EPS | ★ 41.48 | 0.29 |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $11.88 | $1.17 |
| Revenue Next Year | $10.31 | $1.62 |
| P/E Ratio | ★ $18.32 | $94.16 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $476.49 | $7.52 |
| 52 Week High | $821.11 | $29.99 |
| Indicator | REGN | WBD |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 44.46 |
| Support Level | $753.49 | $27.02 |
| Resistance Level | $788.69 | $29.42 |
| Average True Range (ATR) | 17.54 | 0.33 |
| MACD | 3.04 | 0.02 |
| Stochastic Oscillator | 63.70 | 48.94 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Warner Bros. Discovery operates in three segments: streaming, studios, and linear networks. In 2026, it intends to split its networks from streaming and studios to form two separate companies. The streaming business includes HBO Max, which is rapidly increasing its international footprint in addition to its major presence in the US. Studios include industry leaders in both film and television, which produce movies and television series that are monetized in multiple ways, including theatrical release, sales to third parties, and feeding into Warner's own platforms. global networks consist of basic cable networks like CNN, TNT, TBS, Discovery, HGTV, and The Food Network. The Discovery+ streaming service will remain part of global networks.